Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Neurosci ; 25(8): 2319-28, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17445230

RESUMO

The precise ordering of the hamster retinocollicular projection is established over the first two postnatal weeks, coincident with developmental cell death. We have used quantitative retrograde labelling to define topographic precision in the early postnatal projection, to describe its refinement and to assess the contribution played by selective retinal ganglion cell death. The hamster's short gestation period allows the investigation of events occurring prenatally in other rodents. Discrete injections of fluorescent beads in the superior colliculus followed by isodensity contour analysis of labelled retinal cells reveals a dramatic decrease in the extent of retina labelled between postnatal days 2, 6 and 12 (P2, P6, P12): the 20% contour encloses 38.3%, 8.3% and 1.8% of the retina at these ages. Paired injections of two different tracers at variable rostrocaudal (R-C) separations at P2 produced complete overlap of label even when injections were separated by over 1 mm. This was not true for paired mediolateral injections at P2 that were separated by more than 500 microm. Analysis of the segregation of the two tracers ('nearest-neighbour analysis') shows topography improving with age so that by P12 injections separated rostrocaudally by more than 500 microm produced no overlap in the retina. To examine the contribution of selective ganglion cell death to topographic refinement, animals given paired R-C injections at P2 were allowed to survive until P12. Nearest-neighbour analysis reveals significantly more order in the P2-P12 retinae than after overnight survival. Thus, selective cell death plays a small but appreciable role in correction of topographical errors.


Assuntos
Vias Aferentes/crescimento & desenvolvimento , Mapeamento Encefálico/métodos , Morte Celular/fisiologia , Retina/crescimento & desenvolvimento , Colículos Superiores/crescimento & desenvolvimento , Vias Aferentes/anatomia & histologia , Animais , Animais Recém-Nascidos , Cricetinae , Microesferas , Retina/anatomia & histologia , Coloração e Rotulagem/métodos , Colículos Superiores/anatomia & histologia
2.
J Neurosci Methods ; 60(1-2): 211-7, 1995 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-8544481

RESUMO

Implantable sustained-release polymers offer an alternative to osmotic minipumps for the local delivery of drugs to specific brain areas. Here we describe the production of Elvax polymers containing a range of glutamate receptor antagonists and the quantitative characterization of their release properties. Sections of Elvax (200 or 400 microns), prepared by a dimethyl sulphoxide-based method, containing the NMDA antagonist MK-801 or the non-NMDA antagonist CNQX exhibited similar release profiles: an initial 2-week burst followed by a slow decline in release rate over the next 6 weeks. Differences in slice preparation method and thickness or drug concentration and solubility all led to alterations in the level of drug release, but not the overall exponential nature of the release curve. Elvax sections prepared by an aqueous method containing the NMDA antagonists CPP or APV displayed more constant but much lower levels of release than those from the dimethyl sulphoxide-based method. The in vitro release characteristics were compared with in vivo release of MK-801 and the close correspondence observed indicates that the in vitro release data is an accurate predictor of the drug release behaviour of implanted Elvax slices.


Assuntos
Antagonistas de Aminoácidos Excitatórios/administração & dosagem , Polivinil , Receptores de Glutamato/efeitos dos fármacos , 2-Amino-5-fosfonovalerato/administração & dosagem , 2-Amino-5-fosfonovalerato/farmacocinética , 6-Ciano-7-nitroquinoxalina-2,3-diona/administração & dosagem , 6-Ciano-7-nitroquinoxalina-2,3-diona/farmacocinética , 6-Ciano-7-nitroquinoxalina-2,3-diona/farmacologia , Animais , Maleato de Dizocilpina/administração & dosagem , Maleato de Dizocilpina/farmacocinética , Maleato de Dizocilpina/farmacologia , Portadores de Fármacos , Implantes de Medicamento , Antagonistas de Aminoácidos Excitatórios/farmacocinética , Antagonistas de Aminoácidos Excitatórios/farmacologia , Furões , Peso Molecular , N-Metilaspartato/antagonistas & inibidores , Piperazinas/administração & dosagem , Piperazinas/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...